BBIO: Attruby's clinical edge and new launches drive growth, targeting profitability by 2027
China-originated innovation and AI are shaping operational strategies, while regulatory and pricing dynamics remain key. Attruby is driving growth with strong first-line positioning and clinical differentiation, and new launches like infigratinib and BBP-418 are expected to expand market reach and…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.